Zum Hauptinhalt springen
| Hans-Günter Meyer-Thompson | Naltrexon

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. 

Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. 

Roache, J.D., Pavlicova, M., Campbell, A., Choo, T.-H., Peavy, M., Kermack, A.S., Nunes, E.V., Jr. and Rotrosen, J. (2021), 

Alcoholism: Clinical and Experimental Research. Accepted Author Manuscript. doi.org/10.1111/acer.14729

https://onlinelibrary.wiley.com/doi/10.1111/acer.14729